Showcasing Properties & Preclinical Development of ADCs Targeting Integrin Beta-6
- Exploring biology and rationale of targeting integrin beta-6
- Describing early development of ADCs specifically designed to be differentiated from existing ADC therapies
- Spotlighting preclinical data packages that have led to approaching first in human clinical trials